Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

Demolder, Femke;Vanderhelst, Eef;Verbanck, Sylvia;Schleich, Florence;Hanon, Shane;et.al.
(2024) Lung — Vol. 202, n° 4, p. 441-448 (2024)

Files

DemolderFLung2024.pdf
  • Open Access
  • Adobe PDF
  • 703.73 KB
Download

Details

Authors
  • Demolder, Femke
    Author
  • Vanderhelst, Eef
    Author
  • Verbanck, Sylvia
    Author
  • Schleich, Florence
    Author
  • Sohy, CarineUCLouvain
    Author
  • Pilette, CharlesUCLouvain
    Author
  • Hanon, Shane
    Author
Show more
Abstract
(en) BACKGROUND: Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics. METHODS: We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR). RESULTS: 914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV1 in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic. CONCLUSION: In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV1 improvement as compared to SA patients without NP was observed.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Demolder, F., Vanderhelst, E., Verbanck, S., Schleich, F., Louis, R., Brusselle, G., Sohy, C., Michils, A., Peché, R., Pilette, C., & Hanon, S. (2024). Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry. Lung, 202(4), 441-448. https://doi.org/10.1007/s00408-024-00715-0 (Original work published 2024)